On 7 December, IFPMA submitted a statement to the 6th Meeting of the Working Group on Amendments to the International Health Regulations (2005), happening in Geneva, Switzerland.
In view of a growing complexity of product lifecycle management, industry puts forward perspectives to support the harmonization of regulatory requirements. These are intended to facilitate efficient regulatory review and approval to support timely implementation of changes and product improvements, leading to more resilient supply chains.
The study “The Socio-Economic Value of Adult Immunization” by the Office of Health Economics (OHE) synthesizes existing evidence for the broad, socio-economic value of adult immunization programs. It focuses on influenza, pneumococcal, herpes zoster (HZ), and respiratory syncytial virus (RSV) programs in 10 countries where the vaccines have been publicly recommended (Australia, Brazil, France, Germany,...
On 3 December, ABPI, EFPIA, Farmindustria, IFPMA, IMC, JPMA, Leem, PhRMA, and vfa issued a joint statement on climate and health at the 2023 UN Conference on Climate Change, referred to as COP28. The COP28 is taking place 30 November-12 December in Dubai, UAE.
The Biopharmaceutical CEO Roundtable (BCR), which represents the world’s leading biopharmaceutical companies, met in New York on 28 November 2023, to discuss global health challenges and public health policies impacting biomedical innovation. 1 December 2023, New York City – The CEOs of leading biopharmaceutical companies met to focus on global health challenges and the importance...
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and H3D Foundation have today announced a new three-year phase of their partnership, aiming to boost the skills and capacity needed to drive increased research and development of new medicines in Africa.
To mark World Antimicrobial Awareness Week (WAAW) 2023, the International Alliance of Patients’ Organizations (IAPO), the IAPO Patients for Patient Safety Observatory and its AMR Patient Alliance, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the World Medical Association (WMA), the International Council of Nurses (ICN) and International Pharmaceutical Federation (FIP), call for cross-sectoral collaboration to address the growing threat of AMR.
This study by the Office of Health Economics (OHE) synthesizes existing evidence for the broad, socio-economic value of adult immunization programs, focusing on influenza, pneumococcal, herpes zoster (HZ), and respiratory syncytial virus (RSV) programs in ten countries (Australia, Brazil, France, Germany, Italy, Japan, Poland, South Africa, Thailand, United States). In a forthcoming publication, OHE will...
IFPMA’s Thomas Cueni to retire in April 2024, with Dr. David Reddy succeeding him as Director General
On 6 November in Geneva, IFPMA delivered a statement at the seventh meeting of the Intergovernmental Negotiating Body on the Pandemic Accord.
On 2 November, IFPMA and its member associations in South Korea, Singapore and Switzerland have welcomed the appointment of the Korean Ministry of Food and Drug Safety (MFDS) of South Korea, the Health Sciences Authority (HSA) of Singapore, and Swissmedic of Switzerland as the first three Listed Authorities under the WHO Listed Authorities (WLA) framework.
On 2 November in New Delhi, India, IFPMA submitted a statement on Universal Health Coverage (UHC) at the 76th session of WHO Regional Committee for South-East Asia.